Administration of benralizumab in a patient with severe asthma admitted to the intensive care unit with COVID-19 pneumonia: Case report

Johannes Anthon Kroes*, Sander Wilhelm Zielhuis, Carina Bethlehem, Anneke Ten Brinke, Eric Nico Van Roon

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)
8 Downloads (Pure)

Abstract

A patient with severe asthma on benralizumab therapy was admitted to the intensive care unit (ICU) for a coronavirus disease 2019 (COVID-19) infection. At the end of the 8 week benralizumab dosing interval, discussion arose as to whether benralizumab should be administered or if treatment should be discontinued, due to the lack of experience with benralizumab in this situation. Severe broncho-obstruction developed, and the next injection of benralizumab was administered during ICU admission without detrimental symptoms. With this case report, we would like to share our experience with the safe administration of benralizumab during COVID-19 pneumonia, guiding doctors in future decision making.

Original languageEnglish
Pages (from-to)235-236
Number of pages2
JournalEuropean Journal of Hospital Pharmacy: Science and Practice
Volume29
Early online date21-Apr-2021
DOIs
Publication statusPublished - 2022

Cite this